Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Phathom Pharmaceuticals ( (PHAT) ) has provided an update.
On June 16, 2025, Phathom Pharmaceuticals announced that the FDA updated the Orange Book to reflect a full 10-year period of non-patent New Chemical Entity exclusivity for VOQUEZNA tablets. This correction confirms VOQUEZNA’s exclusivity through May 3, 2032, supporting its long-term commercial potential and aligning with statutory requirements.
The most recent analyst rating on (PHAT) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Phathom Pharmaceuticals stock, see the PHAT Stock Forecast page.
Spark’s Take on PHAT Stock
According to Spark, TipRanks’ AI Analyst, PHAT is a Neutral.
Phathom Pharmaceuticals faces significant financial challenges, with high net losses and negative cash flows weighing heavily on its score. Technical analysis shows positive momentum, but valuation concerns persist due to negative profitability metrics. Recent corporate events, including FDA approval for exclusivity, offer some positive outlook, but overall instability remains a concern.
To see Spark’s full report on PHAT stock, click here.
More about Phathom Pharmaceuticals
Phathom Pharmaceuticals operates in the pharmaceutical industry, focusing on developing and commercializing innovative treatments for gastrointestinal diseases.
Average Trading Volume: 2,717,130
Technical Sentiment Signal: Buy
Current Market Cap: $742.8M
For a thorough assessment of PHAT stock, go to TipRanks’ Stock Analysis page.